Cargando…

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets

Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitale, Rosa Maria, Iannotti, Fabio Arturo, Amodeo, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124847/ https://www.ncbi.nlm.nih.gov/pubmed/34062987 http://dx.doi.org/10.3390/ijms22094876

Ejemplares similares

Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation
por: Vitale, Rosa Maria, et al.
Publicado: (2021)

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders
por: Scarante, Franciele F., et al.
Publicado: (2021)

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
por: Silvestro, Serena, et al.
Publicado: (2020)

Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action
por: Ożarowski, Marcin, et al.
Publicado: (2021)

Editorial: “Small molecules targeting transmembrane receptors and ion channels in drug discovery”
por: Vitale, Rosa Maria, et al.
Publicado: (2023)

Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARγ Agonist via a Combined Computational and Functional Study
por: Iannotti, Fabio Arturo, et al.
Publicado: (2020)

The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation
por: Iannotti, Fabio Arturo, et al.
Publicado: (2021)

Neurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders
por: Ratner, Marcia H., et al.
Publicado: (2019)

Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
por: Mlost, Jakub, et al.
Publicado: (2020)

Parasitic pharmacology: A plausible mechanism of action for cannabidiol
por: Groeneveld, Geert Jan, et al.
Publicado: (2019)

Neurological and neuropsychiatric disorders associated with COVID-19. Part II: neuropsychiatric disorders and final consideration
por: Giacalone, Martina, et al.
Publicado: (2021)

Neurological and neuropsychiatric disorders associated with COVID-19. Part I: overview and neurological disorders
por: Giacalone, Martina, et al.
Publicado: (2021)

Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review
por: Jha, Niraj Kumar, et al.
Publicado: (2022)

Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review
por: Matheson, Justin, et al.
Publicado: (2022)

Molecular and Cellular Mechanisms of Action of Cannabidiol
por: Martinez Naya, Nadia, et al.
Publicado: (2023)

The pharmacology and therapeutic role of cannabidiol in diabetes
por: Zhang, Jin, et al.
Publicado: (2023)

Cannabidiol: potential in treatment of neurological diseases, flax as a possible natural source of cannabidiol
por: Storozhuk, Maksim V.
Publicado: (2023)

Editorial: Non-invasive brain stimulation techniques in neurological and neuropsychiatric disorders: Physiological and molecular evidence
por: Cambiaghi, Marco, et al.
Publicado: (2023)

Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review
por: Singh, Kuldeep, et al.
Publicado: (2023)

The Olfactory System as Marker of Neurodegeneration in Aging, Neurological and Neuropsychiatric Disorders
por: Bhatia-Dey, Naina, et al.
Publicado: (2021)

The role of Gadd45b in neurologic and neuropsychiatric disorders: An overview
por: Shen, Xiao-yue, et al.
Publicado: (2022)

Benefits of the Neurogenic Potential of Melatonin for Treating Neurological and Neuropsychiatric Disorders
por: Potes, Yaiza, et al.
Publicado: (2023)

Alternative patterns of deep brain stimulation in neurologic and neuropsychiatric disorders
por: Najera, Ricardo A., et al.
Publicado: (2023)

Cannabidiol and Sodium Channel Pharmacology: General Overview, Mechanism, and Clinical Implications
por: Ghovanloo, Mohammad-Reza, et al.
Publicado: (2021)

nNOS-mediated protein-protein interactions: promising targets for treating neurological and neuropsychiatric disorders
por: Gu, Yuanyuan, et al.
Publicado: (2021)

Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders
por: Lam, Patricia, et al.
Publicado: (2023)

Marine Natural and Nature-Inspired Compounds Targeting Peroxisome Proliferator Activated Receptors (PPARs)
por: D’Aniello, Enrico, et al.
Publicado: (2023)

Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
por: Umpierrez, Laísa S., et al.
Publicado: (2022)

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
por: Montoya, Zackary, et al.
Publicado: (2020)

nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story
por: Zhu, Li-Juan, et al.
Publicado: (2023)

Molecular mechanism of TRPV2 channel modulation by cannabidiol
por: Pumroy, Ruth A, et al.
Publicado: (2019)

From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?
por: Bitencourt, Rafael M., et al.
Publicado: (2021)

BDNF Therapeutic Mechanisms in Neuropsychiatric Disorders
por: Bazzari, Amjad H., et al.
Publicado: (2022)

Editorial: Molecular mechanisms of neuropsychiatric diseases
por: Moreira-Rodrigues, Mónica, et al.
Publicado: (2022)

Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update
por: Asgharian, Parina, et al.
Publicado: (2022)

The Significance of the Default Mode Network (DMN) in Neurological and Neuropsychiatric Disorders: A Review
por: Mohan, Akansha, et al.
Publicado: (2016)

In Silico Identification and Experimental Validation of (−)-Muqubilin A, a Marine Norterpene Peroxide, as PPARα/γ-RXRα Agonist and RARα Positive Allosteric Modulator
por: D’Aniello, Enrico, et al.
Publicado: (2019)

Editorial: Neurological Soft Signs in Neuropsychiatric Conditions
por: Toro, Pablo, et al.
Publicado: (2019)

Neurological, neuropsychiatric and neurodevelopmental complications of COVID-19
por: Pantelis, Christos, et al.
Publicado: (2020)

Cannabidiol and Neurodevelopmental Disorders in Children
por: Kwan Cheung, Keith A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8he7ku90c4jgb9t9lkoqkj30c